专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US09506063B2 SiRNA compositions and methods for treatment of HPV and other infections 有权
标题翻译：用于治疗HPV和其他感染的SiRNA组合物和方法
公开(公告)号：US09506063B2
公开(公告)日：2016-11-29
申请号：US13752568
申请日：2013-01-29
申请人： Alan Y. Lu , Patrick Y. Lu , David M. Evans , John J. Xu
发明人： Alan Y. Lu , Patrick Y. Lu , David M. Evans , John J. Xu
IPC分类号： C12N15/113
CPC分类号： C12N15/1131 , C12N2310/14 , C12N2310/17 , C12N2320/31
摘要： The invention provides siRNA compositions that (1) interfere with viral replication of human papillomavirus (HPV), herpes simplex virus (HSV), and human immunodeficiency virus (HIV) in mucosal tissues, such as genital tissues, and (2) treat fungal infections. The compositions include siRNA molecules that target HPV, complexed with a dendrimer that treats and prevents genital herpes (HSV) and HIV. The compositions also include siRNA molecules that target HPV, complexed with a histidine-lysine (HK) polymer that treats and prevent fungus infection. The combined formulations of siRNA and dendrimer provide treatment of the infections from HPVs, HSVs, and HIVs. The combined formulations of siRNA and HK polymer provide treatment of HPVs and fungus infections.
摘要翻译：本发明提供了siRNA组合物，其（1）干扰人乳头状瘤病毒（HPV），单纯疱疹病毒（HSV）和人类免疫缺陷病毒（HIV）在粘膜组织如生殖器官组织中的病毒复制，和（2）治疗真菌感染。组合物包括靶向HPV的siRNA分子，与治疗和预防生殖器疱疹（HSV）和HIV的树突状细胞复合。组合物还包括靶向HPV的siRNA分子，与治疗和预防真菌感染的组氨酸 - 赖氨酸（HK）聚合物复合。 siRNA和树枝状大分子的组合制剂提供了对HPV，HSV和HIV感染的治疗。 siRNA和HK聚合物的组合制剂提供对HPV和真菌感染的治疗。

2. 发明申请

US20130345284A1 siRNA Compositions and Methods for Treatment of HPV and Other Infections 有权
标题翻译：用于治疗HPV和其他感染的siRNA组合物和方法
公开(公告)号：US20130345284A1
公开(公告)日：2013-12-26
申请号：US13752568
申请日：2013-01-29
申请人： Alan Y. Lu , Patrick Y. Lu , David M. Evans , John J. Xu
发明人： Alan Y. Lu , Patrick Y. Lu , David M. Evans , John J. Xu
IPC分类号： C12N15/113
CPC分类号： C12N15/1131 , C12N2310/14 , C12N2310/17 , C12N2320/31
摘要： The invention provides siRNA compositions that (1) interfere with viral replication of human papillomavirus (HPV), herpes simplex virus (HSV), and human immunodeficiency virus (HIV) in mucosal tissues, such as genital tissues, and (2) treat fungal infections. The compositions include siRNA molecules that target HPV, complexed with a dendrimer that treats and prevents genital herpes (HSV) and HIV. The compositions also include siRNA molecules that target HPV, complexed with a histidine-lysine (HK) polymer that treats and prevent fungus infection. The combined formulations of siRNA and dendrimer provide treatment of the infections from HPVs, HSVs, and HIVs. The combined formulations of siRNA and HK polymer provide treatment of HPVs and fungus infections.
摘要翻译：本发明提供了siRNA组合物，其（1）干扰人乳头状瘤病毒（HPV），单纯疱疹病毒（HSV）和人类免疫缺陷病毒（HIV）在粘膜组织如生殖器官组织中的病毒复制，和（2）治疗真菌感染。组合物包括靶向HPV的siRNA分子，与治疗和预防生殖器疱疹（HSV）和HIV的树突状细胞复合。组合物还包括靶向HPV的siRNA分子，与治疗和预防真菌感染的组氨酸 - 赖氨酸（HK）聚合物复合。 siRNA和树枝状大分子的组合制剂提供了对HPV，HSV和HIV感染的治疗。 siRNA和HK聚合物的组合制剂提供对HPV和真菌感染的治疗。

3. 发明申请

US20130123330A1 Dual Targeted siRNA Therapeutics for Treatment of Diabetic Retinopathy and Other Ocular Neovascularization Diseases 审中-公开
标题翻译：用于治疗糖尿病性视网膜病变和其他眼部新血管形成疾病的双靶向siRNA治疗剂
公开(公告)号：US20130123330A1
公开(公告)日：2013-05-16
申请号：US13549514
申请日：2012-07-15
申请人： Patrick Y. Lu , John J. Xu , Alan Y. Lu
发明人： Patrick Y. Lu , John J. Xu , Alan Y. Lu
IPC分类号： A61K31/713
CPC分类号： A61K31/713 , A61K2300/00
摘要： The present invention relates to compositions and methods for treating diabetic retinopathy and other ocular neovascularization diseases. In one embodiment, the composition comprises at least two different siRNA duplexes and a pharmaceutically acceptable carrier. One of the duplexes binds to an mRNA molecule that encodes VEGF, and the other binds to an mRNA molecule that encodes VEGFR2. In another embodiment, the composition further comprises an siRNA duplex that binds to an mRNA molecule that encodes TGFβ1.
摘要翻译：本发明涉及用于治疗糖尿病性视网膜病变和其它眼部新血管形成疾病的组合物和方法。在一个实施方案中，组合物包含至少两种不同的siRNA双链体和药学上可接受的载体。双链体之一与编码VEGF的mRNA分子结合，另一个与编码VEGFR2的mRNA分子结合。在另一个实施方案中，组合物还包含与编码TGFbeta1的mRNA分子结合的siRNA双链体。

4. 发明授权

US09642873B2 Combinations of TGFβ and COX-2 inhibitors and methods for their therapeutic application 有权
公开(公告)号：US09642873B2
公开(公告)日：2017-05-09
申请号：US13695073
申请日：2011-05-04
申请人： Patrick Y. Lu , Vera Simonenko , David Evans , John J. Xu
发明人： Patrick Y. Lu , Vera Simonenko , David Evans , John J. Xu
IPC分类号： C07H21/04 , C07H21/02 , A61K48/00 , A61K31/713 , C12N15/113 , A61K45/06
CPC分类号： A61K31/713 , A61K45/06 , C07H21/02 , C12N15/113 , C12N15/1136 , C12N15/1137 , C12N2310/14 , C12N2320/11 , C12N2320/31 , C12Y114/99001
摘要： The present invention provides compositions and methods for using combinations of TGFβ1 and Cox-2 inhibitors and TGFβ1 and Hoxb13 inhibitors for the treatment of various medical conditions, including skin scaring due to trauma wounds and surgery, corneal and retina scaring due to injury and surgery, internal organ scaring due to injury and surgery, heart tissue scaring due to heart attack and surgery, and lung, liver, and kidney fibrosis due to inflammation and injury. One example is to use siRNA inhibitors to silence TGFβ1 and Cox-2 at the same time, resulting in significant less scar formation.

5. 发明申请

US20130225655A1 Combinations of TGFBeta and COX-2 Inhibitors and Methods for Their Therapeutic Application 有权
标题翻译： TGFBeta和COX-2抑制剂的组合及其治疗应用的方法
公开(公告)号：US20130225655A1
公开(公告)日：2013-08-29
申请号：US13695073
申请日：2011-05-04
申请人： Patrick Y. Lu , Vera Simonenko , David Evans , John J. Xu
发明人： Patrick Y. Lu , Vera Simonenko , David Evans , John J. Xu
IPC分类号： A61K31/713 , C07H21/02 , A61K45/06
CPC分类号： A61K31/713 , A61K45/06 , C07H21/02 , C12N15/113 , C12N15/1136 , C12N15/1137 , C12N2310/14 , C12N2320/11 , C12N2320/31 , C12Y114/99001
摘要： The present invention provides compositions and methods for using combinations of TGFβ1 and Cox-2 inhibitors and TGFβ1 and Hoxb13 inhibitors for the treatment of various medical conditions, including skin scaring due to trauma wounds and surgery, corneal and retina scaring due to injury and surgery, internal organ scaring due to injury and surgery, heart tissue scaring due to heart attack and surgery, and lung, liver, and kidney fibrosis due to inflammation and injury. One example is to use siRNA inhibitors to silence TGFβ1 and Cox-2 at the same time, resulting in significant less scar formation.
摘要翻译：本发明提供了使用TGFbeta1和Cox-2抑制剂和TGFbeta1和Hoxb13抑制剂的组合的组合物和方法，用于治疗各种医疗状况，包括由创伤伤口和手术引起的皮肤灼伤，由于损伤和手术引起的角膜和视网膜的惊吓，由于受伤和手术引起的内部器官惊吓，心脏病发作和手术引起的心脏组织惊厥，以及炎症和损伤引起的肺，肝，肾纤维化。一个实例是使用siRNA抑制剂同时沉默TGFbeta1和Cox-2，导致显着较少的瘢痕形成。

6. 发明授权

US09012622B2 Compositions and methods using siRNA molecules and siRNA cocktails for the treatment of breast cancer 有权
标题翻译：使用siRNA分子和siRNA鸡尾酒治疗乳腺癌的组合物和方法
公开(公告)号：US09012622B2
公开(公告)日：2015-04-21
申请号：US13141122
申请日：2009-12-31
申请人： Patrick Y. Lu , David Evans , Jun John Xu
发明人： Patrick Y. Lu , David Evans , Jun John Xu
IPC分类号： C07H21/04 , C12N15/113
CPC分类号： C12N15/113 , C12N15/1135 , C12N15/1136 , C12N15/1137 , C12N15/1138 , C12N2310/11 , C12N2310/113 , C12N2310/17 , C12N2320/31 , C12N2320/32
摘要： The present invention provides small interfering RNA (siRNA) molecules, compositions containing the molecules, and methods of using the molecules and compositions to treat breast cancer. In one aspect, a multi-targeted siRNAi cocktail is disclosed. The siRNA molecules may be encapsulated in nanoparticles to further enhance their anti-cancer activity. The compositions may also be used in combination with other anti-cancer agents, such as bevacizumab.
摘要翻译：本发明提供小干扰RNA（siRNA）分子，含有该分子的组合物，以及使用该分子和组合物治疗乳腺癌的方法。一方面，公开了一种多靶向siRNAi混合物。 siRNA分子可以包封在纳米颗粒中以进一步增强其抗癌活性。组合物也可以与其它抗癌剂如贝伐珠单抗联合使用。

7. 发明申请

US20110124710A1 COMPOSITION AND METHODS OF RNAI THERAPEUTICS FOR TREATMENT OF CANCER AND OTHER NEOVASCULARIZATION DISEASES 审中-公开
标题翻译：用于治疗癌症和其他新生血管疾病的RNAI治疗剂的组合物和方法
公开(公告)号：US20110124710A1
公开(公告)日：2011-05-26
申请号：US13005688
申请日：2011-01-13
申请人： Yijia Liu , Patrick Y. Lu , Martin C. Woodle , Frank Y. Xie
发明人： Yijia Liu , Patrick Y. Lu , Martin C. Woodle , Frank Y. Xie
IPC分类号： C07H21/02 , A61K31/7105 , C12N5/09 , A61P35/04
CPC分类号： A61K31/70 , A61K9/5146 , A61K48/00
摘要： Compositions and methods are provided for treatment of diseases involving unwanted neovascularization (NV). The invention provides treatments that control NV through selective inhibition of pro-angiogenic biochemical pathways, including inhibition of the VEGF pathway gene expression and inhibition localized at pathological NV tissues. Tissue targeted nanoparticle compositions comprising polymer conjugates and nucleic acid molecules that induce RNA interference (RNAi) are provided. The nanoparticle compositions of the invention can be used alone or in combination with other therapeutic agents such as VEGF pathway antagonists. The compositions and methods can be used for the treatment of NV diseases such as cancer, ocular disease, arthritis, and inflammatory diseases.
摘要翻译：提供组合物和方法用于治疗涉及不想要的新血管形成（NV）的疾病。本发明提供通过选择性抑制促血管生成生物化学途径来控制NV的治疗，包括VEGF通路基因表达的抑制和局部在病理性NV组织的抑制。提供了包含聚合物缀合物和诱导RNA干扰（RNAi）的核酸分子的组织靶向纳米颗粒组合物。本发明的纳米颗粒组合物可以单独使用或与其它治疗剂如VEGF途径拮抗剂组合使用。组合物和方法可用于治疗NV疾病如癌症，眼病，关节炎和炎性疾病。

8. 发明授权

US07534878B2 Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases 失效
标题翻译：用于治疗癌症和其他新血管形成疾病的RNAi治疗剂的组合物和方法
公开(公告)号：US07534878B2
公开(公告)日：2009-05-19
申请号：US11824085
申请日：2007-06-29
申请人： Yijia Liu , Patrick Y. Lu , Martin C. Woodle , Frank Y. Xie
发明人： Yijia Liu , Patrick Y. Lu , Martin C. Woodle , Frank Y. Xie
IPC分类号： C07H21/04 , C07H21/02 , A61K48/00
CPC分类号： A61K48/00 , A61K9/0019 , A61K9/0048 , A61K9/5146 , A61K31/70 , C12N15/1136 , C12N15/1138 , C12N2310/14 , C12N2310/53 , C12N2320/31 , C12N2320/32
摘要： Compositions and methods are provided for treatment of diseases involving unwanted neovascularization (NV). The invention provides treatments that control NV through selective inhibition of pro-angiogenic biochemical pathways, including inhibition of the VEGF pathway gene expression and inhibition localized at pathological NV tissues. Tissue targeted nanoparticle compositions comprising polymer conjugates and nucleic acid molecules that induce RNA interference (RNAi) are provided. The nanoparticle compositions of the invention can be used alone or in combination with other therapeutic agents such as VEGF pathway antagonists. The compositions and methods can be used for the treatment of NV diseases such as cancer, ocular disease, arthritis, and inflammatory diseases.
摘要翻译：提供组合物和方法用于治疗涉及不想要的新血管形成（NV）的疾病。本发明提供通过选择性抑制促血管生成生物化学途径来控制NV的治疗，包括VEGF通路基因表达的抑制和局部在病理性NV组织的抑制。提供了包含聚合物缀合物和诱导RNA干扰（RNAi）的核酸分子的组织靶向纳米颗粒组合物。本发明的纳米颗粒组合物可以单独使用或与其它治疗剂如VEGF途径拮抗剂组合使用。组合物和方法可用于治疗NV疾病如癌症，眼病，关节炎和炎性疾病。

9. 发明授权

US07893243B2 Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases 失效
标题翻译：用于治疗癌症和其他新血管形成疾病的RNAi治疗剂的组合物和方法
公开(公告)号：US07893243B2
公开(公告)日：2011-02-22
申请号：US11824084
申请日：2007-06-29
申请人： Yijia Liu , Patrick Y. Lu , Martin C. Woodle , Frank Y. Xie
发明人： Yijia Liu , Patrick Y. Lu , Martin C. Woodle , Frank Y. Xie
IPC分类号： C07H21/04 , C07H21/02 , A61K48/00
CPC分类号： A61K48/00 , A61K9/0019 , A61K9/0048 , A61K9/5146 , A61K31/70 , C12N15/1136 , C12N15/1138 , C12N2310/14 , C12N2310/53 , C12N2320/31 , C12N2320/32
摘要： Compositions and methods are provided for treatment of diseases involving unwanted neovascularization (NV). The invention provides treatments that control NV through selective inhibition of pro-angiogenic biochemical pathways, including inhibition of the VEGF pathway gene expression and inhibition localized at pathological NV tissues. Tissue targeted nanoparticle compositions comprising polymer conjugates and nucleic acid molecules that induce RNA interference (RNAi) are provided. The nanoparticle compositions of the invention can be used alone or in combination with other therapeutic agents such as VEGF pathway antagonists. The compositions and methods can be used for the treatment of NV diseases such as cancer, ocular disease, arthritis, and inflammatory diseases.
摘要翻译：提供组合物和方法用于治疗涉及不想要的新血管形成（NV）的疾病。本发明提供通过选择性抑制促血管生成生物化学途径来控制NV的治疗，包括VEGF通路基因表达的抑制和局部在病理性NV组织的抑制。提供了包含聚合物缀合物和诱导RNA干扰（RNAi）的核酸分子的组织靶向纳米颗粒组合物。本发明的纳米颗粒组合物可以单独使用或与其它治疗剂如VEGF途径拮抗剂组合使用。组合物和方法可用于治疗NV疾病如癌症，眼病，关节炎和炎性疾病。

10. 发明授权

US07781414B2 Targets for tumor growth inhibition 失效
标题翻译：靶向肿瘤生长抑制
公开(公告)号：US07781414B2
公开(公告)日：2010-08-24
申请号：US10551667
申请日：2004-04-01
申请人： Patrick Y. Lu , Frank Y. Xie , Martin C. Woodle , Yijia Liu , Quinn Q. Tang , Jun Xu
发明人： Patrick Y. Lu , Frank Y. Xie , Martin C. Woodle , Yijia Liu , Quinn Q. Tang , Jun Xu
IPC分类号： A61K31/70 , C07H21/04 , C07H21/00 , C12P19/34
CPC分类号： C12Q1/6886 , A61K48/00 , A61K2039/53 , C07K14/4748 , C07K14/475 , C07K14/71 , C07K16/30 , C12N15/111 , C12N15/1135 , C12N15/1138 , C12N2310/14 , C12N2320/12 , C12Q2600/112 , G01N33/57407 , G01N2500/00
摘要： The present invention relates to methods for treating cancers by manipulating a target gene expression by up-regulation, silencing and/or down-regulation of the gene, such as EGFR-RP, TRA1, MFGE8, TNFSF13 and ZFP236, respectively. The methods are useful in treating cancers and/or inhibiting tumor growth by enhancing expression of a gene that is validated as a target such as ICT1030, for protein, peptide drug and gene therapy modalities; or by RNA interference to silence and/or down-regulate targets such as ICT1024, ICT1025 and ICT1031 and ICB1003 that are validated for antibody, small molecule and other inhibitor drug modalities.
摘要翻译：本发明涉及通过分别通过上调，沉默和/或下调基因如EGFR-RP，TRA1，MFGE8，TNFSF13和ZFP236来操纵靶基因表达来治疗癌症的方法。该方法可用于通过增强作为靶标的基因（例如ICT1030）的蛋白质，肽药物和基因治疗方式的表达来治疗癌症和/或抑制肿瘤生长; 或通过RNA干扰来沉默和/或下调诸如针对抗体，小分子和其他抑制剂药物形态验证的ICT1024，ICT1025和ICT1031和ICB1003的靶标。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式